Announcements Trials
Browse Landscape

Phase

Phase 1 13Phase 1/2 3

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 439Neoplasms 364Breast Neoplasms 261Colorectal Neoplasms 245Neoplasm Metastasis 217Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 183Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 126Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 98Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Advanced Tumors × Clear all
NCT07110584 2026-03-05

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Recruiting
235 enrolled

Advanced Tumors

NCT05867771 2023-05-22

A Study of PM1022 in Patients With Advanced Tumors

Biotheus Inc.

Phase 1/2 Unknown
200 enrolled

Advanced Tumors

NCT02419417 2022-06-16

BET

Bristol-Myers Squibb

Phase 1/2 Completed
83 enrolled 47 charts

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡